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Abstract
RNA transcripts encoding the 2C-subtype of serotonin (5HT2C) receptor undergo up to five
adenosine-to-inosine editing events to encode twenty-four protein isoforms. To examine the
effects of altered 5HT2C editing in vivo, we generated mutant mice solely expressing the fully-
edited (VGV) isoform of the receptor. Mutant animals present phenotypic characteristics of
Prader-Willi Syndrome (PWS) including a failure to thrive, decreased somatic growth, neonatal
muscular hypotonia, and reduced food consumption followed by post-weaning hyperphagia.
Though previous studies have identified alterations in both 5HT2C receptor expression and
5HT2C-mediated behaviors in both PWS patients and mouse models of this disorder, to our
knowledge the 5HT2C gene is the first locus outside the PWS imprinted region in which mutations
can phenocopy numerous aspects of this syndrome. These results not only strengthen the link
between the molecular etiology of PWS and altered 5HT2C expression, but also demonstrate the
importance of normal patterns of 5HT2C RNA editing in vivo.
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The conversion of adenosine to inosine (A-to-I) by RNA editing is a widespread RNA
processing event by which genomically encoded sequences are altered through the site-
specific deamination of adenosine residue(s) in precursor and mature mRNA transcripts
(Gott and Emeson, 2000). The majority of well characterized A-to-I editing events involve
non-synonymous codon changes in RNAs encoding proteins involved in nervous system
function including ligand- and voltage-gated ion channels, a G-protein coupled receptor and
components of the synaptic release machinery (Burns et al., 1997; Gott and Emeson, 2000;
Hoopengardner et al., 2003). Transcripts encoding the 5HT2C receptor can be modified by
five A-to-I editing events (sites A-E) to generate as many as 24 protein isoforms that differ
by up to three amino acids within the predicted second intracellular loop of the receptor, a
region involved in receptor:G-protein coupling (Burns et al., 1997; Pin et al., 1994). Though
initial sequence analyses of cDNAs isolated from dissected rat and human brains predicted
the region-specific expression of as many as 12 major 5HT2C receptor isoforms encoded by
eighteen distinct RNA species (Burns et al., 1997; Niswender et al., 1999), more recent
studies identified the expression of 26 of the 32 possible mRNA isoforms and determined
that only 4-6 of these mRNAs represent more than 5% of total 5HT2C transcripts in rats and
humans, respectively (Dracheva et al., 2009). Alterations in 5HT2C receptor editing have
been observed in suicide victims with a history of major depression, schizophrenia, or
bipolar disorder (Dracheva et al., 2008; Gurevich et al., 2002; Iwamoto and Kato, 2003;
Niswender et al., 2001) and in response to antidepressant and antipsychotic treatment
(Englander et al., 2005; Gurevich et al., 2002; Sodhi et al., 2005). The fully-edited (VGV)
isoform of the human 5HT2C receptor, encoding valine, glycine and valine at amino acid
positions 156, 158 and 160, respectively, exhibits reduced constitutive activity and
decreased G-protein coupling efficacy when compared to the genomically-encoded (INI)
isoform in heterologous expression systems (Berg et al., 2001; Burns et al., 1997; Fitzgerald
et al., 1999; Niswender et al., 1999; Wang et al., 2000), yet the physiologic relevance of
5HT2C RNA editing in nervous system function remains unclear.
Prader-Willi Syndrome is a maternally-imprinted human disorder resulting from a loss of
paternal gene expression on chromosome 15q11-13 that is characterized by a complex
phenotype including cognitive deficits, infantile hypotonia and failure to thrive, short
stature, hypogonadism and hyperphagia which can lead to morbid obesity (Goldstone, 2004;
Nicholls and Knepper, 2001). Multiple mouse models with deficiencies of one or more PWS
candidate genes have partially correlated individual genes with aspects of the PWS
phenotype (Bischof et al., 2007; Cattanach et al., 1992; Ding et al., 2008; Gabriel et al.,
1999; Gerard et al., 1999; Muscatelli et al., 2000; Skryabin et al., 2007; Tsai et al., 1999b;
Yang et al., 1998). Among these imprinted candidate genes are the brain-specific small
nucleolar RNAs (snoRNAs), HBII-13, HBII-85 and HBII-52 (Cavaille et al., 2000).
HBII-52 (SNORD115), and its mouse orthologue (MBII-52; Snord115), are members of the
box C/D family of snoRNAs that are responsible for directing the 2′-O-methylation of
specific ribose moieties in pre-ribosomal RNA transcripts and U small nuclear RNAs (Kiss,
2002). HBII-52/MBII-52 is complementary to an 18 nucleotide segment of 5HT2C mRNA
containing three of five editing sites (E, C and D), predicting 2′-O-methylation of the ribose
for the adenosine nucleoside at the C-site (Cavaille et al., 2000), an editing position that can
significantly affect the function of encoded 5HT2C protein isoforms (Burns et al., 1997;
Niswender et al., 1999). HBII-52/MBII-52 also has been observed to affect 5HT2C RNA
editing/splicing patterns using tissue culture model systems (Kishore and Stamm, 2006;
Vitali et al., 2005). Analyses of 5HT2C transcripts have indicated that site-specific editing is
increased in brain samples from both PWS patients (Kishore and Stamm, 2006) and a mouse
model of PWS (PWS-ICdel) that further exhibits deficits in specific 5HT2C-mediated
behaviors (Doe et al., 2009). Though these studies have correlated changes in both 5HT2C
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receptor expression and function in the absence of 15q11-13 gene expression, here we show
that increased 5HT2C RNA editing in mutant mice recapitulates many aspects of this
disorder, suggesting an important role for altered 5HT2C function in the etiology of Prader-
Willi Syndrome.
Materials and Methods
Generation of 5HT2C-VGV mice
A genomic fragment containing a portion of the mouse 5HT2C gene was isolated from a
129S6 BAC library (Genome Systems, St. Louis, MO) and a 7.4-kb Avr II restriction
fragment containing exon 5 and a portion of the flanking introns was subcloned into a
modified pBKSII− vector (Stratagene, La Jolla, CA). The five edited adenosine residues
within exon 5 were mutated to guanosine moieties using overlap-extension PCR (Ho et al.,
1989). A DNA fragment encoding loxP-flanked neomycin phosphotransferase, under control
of the phosphoglycerate kinase (PGK) promoter, was inserted into an endogenous Kpn I site
located 184 bases downstream of the 5′-splice site for exon 5. A selection cassette encoding
PGK-driven herpes simplex virus thymidine kinase was inserted outside the region of
homology as a negative selectable marker. The Not I-linearized targeting vector was
introduced into TL-1 embryonic stem cells by electroporation; cells were selected with
Geneticin® (G418) and ganciclovir and antibiotic resistant clones were screened for
homologous recombination by PCR using the Expand Long Template PCR kit (Roche,
USA) using primers located outside the region of homology (sense, 5′-
CTGAGTGCATTGGAAAAGAGATCC-3′; antisense, 5′-
CCATATATCAGGATGCAGTCTTGTCA-3′). Heterozygous mice obtained from chimeras
were mated to mice expressing Cre recombinase under the control of the mouse protamine 1
promoter (The Jackson Laboratory, Bar Harbor, ME) and mutant male offspring were
screened for the elimination of the loxP-flanked neomycin resistance cassette. Mutations
were verified by DNA sequence analysis and all mice were maintained on the 129S6 strain
(Taconic, USA). PCR-based genotyping was employed using primers upstream of the
editing sites (5′-AATATCAATAGGTAATTATACC-3′) and downstream of the remaining
loxP site within intron 5 (5′-GGGCAAATATTCTGAAAAGATGTT-3′), resulting in the
production of 371 and 468 bp amplicons for the wild-type and mutant alleles, respectively.
Mutant mice heterozygous for the 5HT2C-VGV allele were mated with wild-type 129S6
animals and subsequent offspring were assessed for the presence of the modified allele and
loss of the Cre transgene by segregation.
RNA characterization
Total RNA from male hemizygous 5HT2C-VGV mice and wild-type adult littermates (14
weeks) was isolated from whole brain using Tri-Reagent (Molecular Research Center,
Cincinnati, OH) or from dissected brain regions using the PerfectPure RNA tissue kit (5
Prime, Gaithersburg, MD) according to the manufacturer's instructions with all specimens
processed in an identical manner. To verify that the introduced A-to-G mutations resulted in
the sole production of 5HT2C mRNAs encoding the VGV isoform of the receptor, first-
strand cDNA was synthesized using AMV reverse transcriptase (Promega, Madison, WI)
and amplified using PCR with primers flanking the duplex region (sense primer 5′-
AATATCAATAGGTAATTATACC-3′, antisense primer 5′-
GGGCAAATATTCTGAAAAGATGTT-3′). Resultant PCR amplicons from both
5HT2C-VGV and wild-type mice were subjected to direct dideoxynucleotide sequence
analysis and subsequently subcloned into pBKSII− (Stratagene, La Jolla, CA) where
individual cDNA isolates from each genotype were sequenced.
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Quantification of total and alternatively spliced 5HT2C mRNAs was performed using either
a ribonuclease (RNase) protection assay as described (Emeson et al., 1989), a semi-
quantitative RT-PCR strategy, or real-time RT-PCR. For RNase protection analyses, an
antisense riboprobe directed against 5HT2C pre-mRNA, extending from nucleotide −276 to
+316 (relative to the first nucleotide of exon 6), resulted in protected fragments of 602 and
316 nt for pre-mRNA and total 5HT2C transcripts, respectively. Three additional antisense
riboprobes, specific for alternatively spliced 5HT2C RNA isoforms, were developed to
unique regions of exon 5 (RNA 1, RNA 2) or the proximal region of intron 5 (RNA 3) and
were contiguous with the first 182 nucleotides of exon 6. A cyclophilin antisense probe was
also generated as an internal loading control as previously described (nucleotides +34-144,
GenBank accession number M19533) (Singh et al., 2007). The relative expression of
protected fragments was quantified using a Typhoon 9400 phosphorimager (GE Healthcare,
Piscataway, NJ) with ImageQuant TL software.
Semi-quantitative analysis of 5HT2C mRNA isoform expression by end-point RT-PCR was
performed using primers in exons 5 and 6 (sense, 5′-GATATTTGTGCCCCGTC-3′;
antisense, 5′-ATCAAAGCTTGACGGCGTAGGACGTAG-3′) and amplified for 30 cycles.
Resultant amplicons were resolved on a 2% agarose gel and ethidium bromide fluorescence
was quantified by phosphorimager analysis and values were corrected for the length of each
amplicon. Individual 5HT2C mRNA isoform expression was determined by summing values
corresponding to the RNA1, RNA2, and RNA3 isoforms for each sample and dividing each
isoform expression value by this total.
To determine the steady-state mRNA expression levels for 5HT2A, 5HT2B, 5HT2C, and
5HT7 receptors by quantitative RT-PCR, first-strand cDNA was synthesized using random
hexamers and subjected to Taqman real-time PCR analysis (Applied Biosystems, Foster
City, CA). All primers and probes used for the real-time PCR reactions were products of
Assay-On-Demand from Applied Biosystems, (5HT2A, Assay ID Mm00555764_m1;
5HT2B, Assay ID Mm00434123_m1; 5HT2C, Assay ID Mm00434127_m1; 5HT7, Assay ID
Mm00434133_m1). Eukaryotic 18S rRNA (product # 4319413E, Applied Biosystems) was
included in each multiplex PCR reaction as an internal control. Real-time PCR reactions and
subsequent analyses were performed with the ABI Prism 7900HT Sequence Detection
System (SDS v2.3, Applied Biosystems). To quantify levels of pro-opiomelanocortin
(POMC) and neuropeptide Y (NPY), hypothalamic tissue was dissected by the method of
Glowinski and Iverson (Glowinski and Iversen, 1966); total RNA was isolated and subjected
to real-time RT-PCR as described above (NPY, Assay ID Mm00445771_m1; POMC, Assay
ID Mm00435874_m1). The amplification efficiencies for all reactions were calculated
individually using Real-time PCR Miner software and used to determine the average Ct
value for each sample (Zhao and Fernald, 2005). To achieve an accurate quantification of
target gene expression, target Ct values were normalized to the corresponding 18S rRNA Ct
value for each sample.
Protein expression
Male 5HT2C-VGV mice and wild-type littermates were sacrificed at either P2 or 14 weeks of
age, whole brains were dissected and immediately frozen on dry ice, followed by manual
homogenization in ice-cold sucrose buffer [0.32M sucrose; 10mM K+-HEPES, pH 7.4,
complete EDTA-free protease inhibitor (Roche, Piscataway, NJ)]. After whole cells and
nuclei were eliminated by centrifugation at 1000 × g for 10 minutes, microsomes were
pelleted at 45000 × g for 15 minutes and resuspended in CHAPS lysis buffer (50mM
HEPES, 150mM NaCl, 1mM EDTA, 10mM sodium pyrophosphate, 25mM DTT, 1.5% (w/
v) CHAPS, complete EDTA-free protease inhibitor, pH 7.5) by triturating 10x through a 21-
gauge needle. Insoluble particles were pelleted at 40000 × g for 20 minutes and the resulting
supernatant was incubated overnight with a lectin from Triticum vulgaris conjugated to
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agarose beads (Sigma-Aldrich, St. Louis, MO) at 4°C. Beads were pelleted at 4000 × g for 1
minute, rinsed with wash buffer (50mM HEPES, 150mM NaCl, 0.1% Triton X-100, 10%
glycerol, pH 7.5), and pelleted again. Protein was eluted in 2x SDS sample buffer (125 mM
Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 200 mM DTT, and 0.2% bromophenol blue) at
65°C for 5 minutes before pelleting the beads and loading the supernatant on a 10%
polyacrylamide gel. Following electrophoretic transfer to nitrocellulose, 5HT2C protein
levels were determined by Western blotting analysis using an anti-5HT2C receptor
monoclonal antibody (1:250 [v/v], Santa Cruz Biotechnology, Santa Cruz, CA; SR-2C
(D-12)) and an anti-β-actin monoclonal antibody (1:10000 [v/v], Sigma-Aldrich, St. Louis,
MO; A1978), respectively, followed by an HRP-labeled anti-mouse secondary antibody
(1:1500 [v/v], Vector Labs, Burlingame, CA). The secondary antibody was detected with
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Rockford,
IL).
To quantify receptor expression, saturation binding experiments were performed on
dissected frontal cortex, striatum, and hippocampus from adult animals. Following
anesthesia with isofluorane, mice were cervically dislocated, decapitated, and whole brains
were removed from the cranium. A razor blade was used to coronally block the brain
immediately anterior to the optic chiasm. The anterior portion of the striatum was identified
in the front tissue block. Landmarks used included the white matter separating it from the
overlying cortex and the lateral ventricle separating it from the medial wall of the
telenchephalon. The caudate-putamen was removed and reserved, with the remainder of the
tissue in this block considered frontal cortex. The two hemispheres of the remaining brain
tissue were carefully separated from the dorsal surface using forceps to expose the
hippocampus and the posterior portion of the striatum. Forceps were used to gently separate
both the left and right entire hippocampal structures as a single unit from the rest of the
brain, including CA1, CA2, CA3, and dentate gyrus. Following removal of whole
hippocampus, the posterior portions of the striatum were visually identified by the striated
nature of the tissue and nearby white matter tracts, carefully isolated with forceps, and added
to the anterior striatum previously isolated to complete the striatal sample.
Dissected tissue was mechanically homogenized at 15000 rpm for 10 seconds (Tissue
Tearor; Biospec Products, Bartlesville, OK) in 2 ml of standard binding buffer (SBB, 50
mM Tris-HCl, pH 7.4, 10 mM MgCl2, 0.1 mM EDTA) and then centrifuged at 25000 × g
for 10 minutes. The supernatant was removed and the pellet was resuspended in 1 ml of
SBB and transferred to 1.7 mL eppendorf tubes. The tissue was then spun at 16000 × g in a
microcentrifuge for 5 minutes at 4°C. The supernatant was removed and the tissue pellets
were frozen at −80°C until used for binding experiments. Total binding was determined
using N6-methyl-[3H]-mesulergine (8-point curves were generated using [3H]-mesulergine
concentrations of 0.25, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, and 8.0 nM) with non-specific binding
measured using those same concentrations of [3H]-mesulergine plus 8μM ritanserin; both
sets of conditions included 100 nM spiperone to block 5HT2A receptor binding. Bradford
protein assays were performed to quantify protein in each pellet (BioRad Laboratories,
Hercules, CA). All incubations were performed in SBB for 1.5 hours at room temperature.
Incubations were terminated by rapid filtration using Whatman GF/C glass fiber filters,
washed 3 times with cold 50 mM Tris-HCl (pH 6.9 at room temperature, pH 7.4 at 4°C).
Samples were measured by liquid scintillation spectrometry in a Perkin-Elmer Tri-Carb
2800TR counter. Data were analyzed using GraphPad Prism (Graphpad Software, San
Diego, CA) using nonlinear regression to fit the experimental data to saturation binding
equations (assuming ligand depletion). Bmax values from Graphpad were normalized to
protein concentration as determined using the Bradford assay. Control studies with
membranes from 5HT2C receptor-null mice (Tecott et al., 1995) demonstrated no
appreciable binding (data not shown).
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Mice were maintained on a 12-h light, 12-h dark cycle in a humidity- and temperature-
controlled room with ad libitum access to water and standard laboratory chow (rodent chow
5001; Ralston Purina Co., St. Louis, MO). All animal studies were approved by the
Institutional Animal Care and Use Committee of Vanderbilt University or the University of
Alabama at Birmingham. Growth rates of mutant mice and control littermates were
monitored in separate cohorts either daily prior to weaning (P21) or weekly beginning at
weaning. Cumulative food consumption was assessed for age-matched, adult 5HT2C-VGV
male mice and wild-type littermates using an automated feeding apparatus that measured
free-feeding behavior by allowing animals ad libitum access to food cups that were mounted
on a balance and monitored every 30 seconds (Singh et al., 2007). All feeding studies were
performed after animals have been acclimated to the apparatus for at least 72 hrs. Metabolic
analyses were assessed for age-matched, adult 5HT2C-VGV male mice and wild-type
littermates as previously described (Powell et al., 2002; Singh et al., 2007). Average daily
locomotor activity was monitored by both wheel-running activity and infrared motion
detection for 21 days, following a 7-day acclimation period and analyzed using ClockLab
software (ActiMetrics Software, Wilmette, IL). Acute locomotor activity was measured
using open field chambers (Med Associates, St. Albans, VT) and monitored for 60 minutes
on 3 successive days as described (Crawley, 2008).
To measure pre-weaning food intake, dams were injected with 6.63mg/g 99.9% deuterium
oxide (2H2O; Cambridge Isotope Laboratories, Andover, MA) and pups were injected with
3.33mg/g H 182O (Sigma-Aldrich, St. Louis, MO). A graduated glass tuberculin syringe
(Becton-Dickson, Franklin Lakes, NJ) used to deliver the isotopic tracers was weighed
before and after injection to obtain an accurate mass of the injected dose. Pups were
decapitated and blood was harvested at 6, 36, and 72 hours post-injection, with tail-blood
simultaneously collected from dams. Samples were centrifuged (14,000 × g) at 4°C for 15
minutes and plasma was analyzed by cavity ring-down infrared spectroscopy to determine
the ratios of 2H2O/H2O and H2 18O/H2 16O (Metabolic Solutions, Nashua, NH) (Crosson et
al., 2002). Estimates of water flux in the pups and milk transfer between the dam and pups
were made using the methods of Lifson, et al. (Lee and Lifson, 1960; Lifson, 1966;
McClintock and Lifson, 1957) where the tracer data were expressed as tracer to tracee ratios.
A compartmental model was constructed which described the water dilution space and
turnover in dams and pups based on the respective dose of 2H2O or H2 18O. The original
single isotope method used in animal studies was modified by incorporation of H2 182O to
account for independent water turnover in the pups due to metabolic production of water,
which leads to about 8% bias, if uncorrected (Butte et al., 1988). SAAM II software (SAAM
Institute, University of Washington, Seattle) was used for compartmental analysis (Barrett et
al., 1998). Milk intake by each pup was estimated from the rate of transfer of 2H2O from the
dam to the pup (Infante et al., 1985).
Grip force was measured as described (Meyer et al., 1979) using a force gauge (San Diego
Instruments, San Diego, CA). Muscle endurance and motor coordination were assessed
using an accelerating Rotarod (Ugo Basile, Comerio, Italy) paradigm. Briefly, mice were
placed on a rotating 3.2 cm rod that accelerated from 5-40 revolution/minute over a 5 minute
period; latency to fall off of the rod was measured using a stopwatch. Mice that fell from the
rod within 15 seconds were retested; mice that grasped the rod and rotated with it for ≥2
revolutions were scored as having fallen.
Statistical analysis
Body weight data were analyzed by two-way analysis of variance (ANOVA). The survival
curve was analyzed by the logrank test. Hypothalamic mRNA expression at the P21
Morabito et al. Page 6













timepoint was analyzed by randomized block analysis to eliminate variability in
independently collected sample sets. All other data were analyzed by two-tailed Student's t
test; for data sets with unequal variances, Welch's correction was applied. P values less than
0.05 were considered significant.
Results
Generation of mutant mice solely expressing the fully-edited (VGV) isoform of the 5HT2C
receptor
To investigate the importance of normal 5HT2C RNA editing patterns, we generated mutant
mice solely expressing the fully-edited isoform of the receptor (5HT2C-VGV). We chose this
receptor isoform based upon its decreased G-protein coupling efficacy and lack of
constitutive activity compared to other 5HT2C isoforms (Berg et al., 2001; Burns et al.,
1997; Fitzgerald et al., 1999; Niswender et al., 1999; Wang et al., 2000). Mice solely
expressing 5HT2C-VGV receptors were generated by homologous recombination using a
replacement-type targeting vector with the five edited adenosine residues of the 5HT2C
receptor gene (htr2C) mutated to guanosine to mimic the base-pairing properties of inosine
(Figs. 1A and B). Since the mouse 5HT2C gene is located on the X chromosome, obtaining
all possible genotypes of mutant mice and wild-type littermates required two distinct
breeding strategies (Table 1). The resultant offspring were genotyped at weaning (postnatal
day 21; P21) and demonstrated a normal Mendelian distribution (Fig. 1C and Table 1),
indicating that the 5HT2C-VGV mutation does not result in embryonic or early postnatal
lethality. To confirm that mutant mice bearing the modified 5HT2C-VGV allele expressed
transcripts solely encoding the VGV isoform of the receptor, whole-brain derived cDNA
was generated by reverse-transcription polymerase chain reaction (RT-PCR) amplification
of 5HT2C pre-mRNA and the resulting amplicon was sequenced directly. Complementary
DNA from wild-type animals exhibited overlapping adenosine/guanosine peaks in
electropherogram traces resulting from a mixture of edited 5HT2C transcripts, whereas
cDNAs from mutant animals showed only VGV-encoding guanosine moieties at the five
editing sites (Fig. 1D). Due to potential alterations in the structure of the extended RNA
duplex required for site-selective A-to-I conversion (Burns et al., 1997) resulting from the
introduced guanosine mutations at the five editing sites, further sequence analysis of 50
individual cDNA clones derived from 5HT2C pre-mRNAs indicated no aberrant editing
throughout the predicted region of double-stranded RNA and sole expression of the VGV
isoform in 5HT2C-VGV mice (data not shown).
Altered 5HT2C expression in VGV mutant mice
Co-expression of the HBII-52 snoRNA with 5HT2C minigenes has been shown to direct
distal 5′-splice site selection in heterologous expression systems through blockade of a
splicing silencer that overlaps with the edited region in exon 5 (Kishore and Stamm, 2006;
Vitali et al., 2005). Editing of the mutant allele at the E, C, and D sites also weakens this
splicing silencer to promote expression of RNA 2 (Fig. 2A) (Flomen et al., 2004), the
5HT2C mRNA isoform encoding the full-length receptor protein (Canton et al., 1996; Wang
et al., 2000), even in the absence of HBII-52/MBII-52 (Kishore and Stamm, 2006). The
other 5HT2C splice variants result from the use of a more proximal splice donor in exon 5
(RNA 1) or a distal 5′-splice site in intron 5 (RNA 3), each encoding truncated receptor
proteins resulting from premature translation termination that are presumed to be
nonfunctional (Fig. 2A) (Canton et al., 1996; Wang et al., 2000). To assess whether the
5HT2C-VGV allele produced alterations in 5HT2C mRNA expression, we employed a
ribonuclease (RNase) protection strategy using an antisense riboprobe that could distinguish
between unspliced premRNA and mature 5HT2C transcripts to quantify the level of 5HT2C
mRNA expression in either whole brain or dissected brain regions (Fig. 2A). Results from
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this analysis revealed no detection of pre-mRNA expression nor any difference in total
5HT2C mRNA levels (RNA 1 + RNA 2 + RNA 3) for whole brain or dissected brain regions
between wild-type and VGV/Y mutant animals (Fig. 2B), although a significant increase
and decrease was observed in the levels of RNA 2 and RNA 1, respectively (Figs. 2C and
D). Similar results for total 5HT2C mRNA expression were observed using a real-time RT-
PCR-based strategy (data not shown). Since expression of RNA 3 was not detectable using
this assay due to its low level of expression, we developed a more sensitive, semi-
quantitative RT-PCR-based strategy to amplify the alternatively spliced region for all three
5HT2C mRNA isoforms with a single primer pair (Fig. 2D). These results revealed no
alteration in RNA 3 expression and confirmed the observed changes in RNA 1 and RNA 2
in mutant mice (Fig. 2C), consistent with previous studies in which increased editing of
5HT2C pre-mRNAs promoted the production of RNA 2 at the expense of RNA 1 (Flomen et
al., 2004).
While no change in the steady-state level of total 5HT2C mRNA was observed in 5HT2C-
VGV mice, mutant animals demonstrated a dramatic increase in receptor protein expression
relative to wild-type littermates (40-to-70-fold) that varied between dissected brain regions
(Fig. 3). Saturation binding with total membrane fractions isolated from frontal cortex,
hippocampus and striatum revealed an increase in maximal binding (Bmax) with no change
in affinity (Kd) for [3H]-mesulergine, a selective 5HT2A/2C antagonist (Fig. 3A). Since
5HT2A receptor binding was blocked by the addition of spiperone (100 nM) to all samples,
these results indicate a specific increase in 5HT2C receptor levels. To determine if a
compensatory increase in the expression of other serotonin receptors that can bind [3H]-
mesulergine is responsible for the observed increase in binding, real-time RT-PCR analyses
were performed to quantify the expression of 5HT2A, 5HT2B and 5HT7 receptors in whole
brain RNA samples. No significant differences in the steady-state levels of 5HT2A and 5HT7
receptor transcripts were observed between wild-type and 5HT2C-VGV mutant animals,
while the expression of 5HT2B mRNA was not detectable in whole brain RNA from either
genotype (data not shown).
We confirmed that the observed differences in 5HT2C protein level did not result from in
vivo differences in pharmacologic properties using a Western blotting strategy from whole
brain samples isolated from neonatal (P2) and adult animals (Fig. 3B). Control studies with
transiently transfected mouse fibroblasts (NIH-3T3) expressing either 5HT2A or 5HT2C
receptors verified antibody specificity (Fig. 3B). While 5HT2C receptor expression was
detected readily in protein samples isolated from the whole brain of individual 5HT2C-VGV
mice at both developmental time points, it was indistinguishable from background in wild-
type animals, owing to the low levels of receptor expression observed in many brain regions
(Fig. 3A, right) (Mengod et al., 1990). These results confirm that the dramatic changes in
5HT2C protein expression observed using radio-ligand binding are due to increases in
receptor protein expression rather than isoform-specific differences in ligand affinity.
Failure to thrive in 5HT 2C-VGV mutant mice
Initial characterization of 5HT2C-VGV mutant animals revealed a 70% decrease in body mass
for hemizygous mutant males (VGV/Y) at P21 despite no significant differences in body
mass at birth (Fig. 4A), suggesting a postnatal failure to thrive. While a similar reduction in
body mass also was observed in homozygous (VGV/VGV) mutant females, heterozygous
mutant females (VGV/+) demonstrated an intermediate growth phenotype indicative of
haploinsufficiency. Mutant animals appeared hypotonic with reduced milk content in their
stomach, subsequently showing clinical signs of dehydration that included piloerection, a
mottled appearance and hunched posture (data not shown). Mutant mice also demonstrated a
post-weaning mortality with 10-20% of mutant offspring dying between P21 and P24 that
could be minimized with nutritional supplementation by placing a wet food paste in the
Morabito et al. Page 8













bottom of the cage. In addition to reduced body mass, mutant mice displayed decreased
linear growth (Fig. 4A, inset), as the body length (nose-to-rump) of VGV/Y males and
control littermates (P21) was 60.4 ± 1.3 mm and 87.6 ± 1.5 mm, respectively (n ≥ 5; p ≤
0.0001). Despite their decreased growth rate prior to P21, all mutant mice bearing the
5HT2C-VGV allele quickly established a normal growth pattern following weaning, gaining
mass at a rate roughly parallel to that of their wild-type littermates (Fig. 4B). A gene-dosage
effect remained evident in female mice, as homozygous mutants weighed significantly less
than heterozygous animals and both groups weighed less than wild-type female littermates
(p ≤ 0.0001). This unusual pattern of growth, switching from an initial failure to thrive to a
post-weaning weight gain that parallels wild-type littermates, is similar to that previously
observed for a mouse model of PWS (PWS-ICdel) in which a 42 kilobase (kb) region was
deleted from the distal portion of the putative mouse imprinting center on chromosome 7
(Chamberlain et al., 2004;Yang et al., 1998).
Altered feeding behavior and increased metabolism in 5HT2C-VGV mice
Infants with PWS initially present with feeding difficulties and a failure to thrive, often
requiring gavage or other medical intervention to maintain proper nutrition (Goldstone,
2004). To determine if the observed failure to thrive in 5HT2C-VGV mice resulted from
similar feeding deficits, we measured milk consumption in mice from postnatal day 9-12.
Offspring derived from a wild-type male x heterozygous mutant female breeding strategy
were genotyped at P8 and the individual litters were culled to 3 pups at P9, with one pup of
each possible genotype represented in each litter (wild-type, VGV/+, and VGV/Y). Pups and
dams were injected with separate, stable heavy water isotopes (H2 18O and 2H20,
respectively) on P9 and the accumulation and clearance of the isotopes was measured at
regular intervals over a 72 hour period. 5HT2C-VGV mice ingested significantly less milk
than wild-type littermates (0.580 ± 0.097 and 1.345 ± 0.301 grams milk/day, respectively; p
< 0.05), with heterozygous mutant animals again exhibiting an intermediate phenotype
(1.092 ± 0.212 grams milk/day), suggesting that decreased pre-weaning milk consumption
contributes to the reduced growth rate of mutant mice.
The 5HT2C receptor has been implicated directly in the anorectic modulation of food intake
using both transgenic and pharmacologic approaches (Heisler et al., 2002; Hewitt et al.,
2002; Nonogaki et al., 1998; Tecott et al., 1995). Despite the 22% reduction in the mean
body mass for adult 5HT2C-VGV mice compared to their wild-type littermates (Fig. 4B), age-
matched adult mutant and wild-type animals consume roughly equivalent amounts of food
(data not shown). Since adult animals of even slightly different weights would be expected
to demonstrate differences in food consumption due to the dominance of anabolic pathways
to increase feeding to maintain adipose mass (Augustine and Rossi, 1999), food intake was
corrected for body mass to reveal that 5HT2C-VGV mice were functionally hyperphagic with
an 18% increase in daily food consumption (Fig. 5A).
Individuals with PWS classically present with hyperphagia and impaired satiety, often
leading to severe obesity in affected patients as young as two years of age (Goldstone,
2004). Despite their hyperphagia, 5HT2C-VGV mice do not become obese and maintain the
7-10 gram reduction in body mass compared to wild-type littermates initially observed at
weaning (Fig. 4B). This absence of obesity was not associated with a corresponding increase
in locomotor activity, as no significant differences were observed between 5HT2C-VGV and
wild-type animals when assessed by home cage analysis of infrared motion detection (Fig.
5B) or wheel running activity (data not shown). However, indirect calorimetry revealed that
5HT2C-VGV mice expend more total and resting energy than wild-type littermates per gram
body mass (Fig. 5C), suggesting that an elevated metabolic rate in mutant animals may
compensate for hyperphagia to prevent the subsequent onset of obesity.
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Perceived energy deficits increase expression of the orexigenic neuropeptide Y (NPY)
(Mizuno et al., 1999) while simultaneously decreasing the expression of anorectic peptides
derived from the pro-opiomelanocortin (POMC) prohormone (Schwartz et al., 1997) to
increase food consumption. Quantitative analysis of hypothalamic RNA expression in
mutant animals revealed a 22-89% increase in NPY mRNA relative to wild-type mice at all
time points examined, whereas steady-state POMC mRNA levels were significantly
decreased 76% at weaning (P21), 29% at 14 weeks and 33% at 36 weeks of age, but were
unaltered at P4 (Fig. 5D). These changes in hypothalamic neuropeptide mRNA expression
are consistent with the observed post-weaning increase in food consumption in 5HT2C-VGV
animals (Ellacott and Cone, 2004).
5HT2C-VGV mice display additional PWS characteristics observed in humans or mouse
models
Infants affected with PWS exhibit other nonspecific symptoms including hypotonia and
growth retardation (Goldstone, 2004), with similar phenotypes also observed in several
mouse models of PWS (Ding et al., 2008; Gabriel et al., 1999; Skryabin et al., 2007; Tsai et
al., 1999b; Yang et al., 1998). To examine potential changes in muscle tone, we initially
employed an accelerating Rotarod® paradigm. Recently weaned wild-type animals
outperformed their mutant littermates on this task, with no difference observed in adults
(Fig. 6A). Since decreased performance using the Rotarod® could reflect alterations in either
muscle tone or motor coordination, we also measured the grip strength of wild-type and
hemizygous male 5HT2C-VGV mice (Fig. 6B). Though no differences were observed in adult
mice, weanling mutant animals (P21-P28) exhibited a ~50% reduction in grip force,
suggesting that an early hypotonia in 5HT2C-VGV mice improves with age similar to patients
affected with PWS (Goldstone, 2004).
Several previously described murine models of PWS report feeding difficulties, failure to
thrive and/or growth deficiency, yet the utility of these models has been hampered by
substantial neonatal lethality (Cattanach et al., 1992; Gerard et al., 1999; Tsai et al., 1999b;
Yang et al., 1998). More recent studies have identified permissive (FVB/NJ, C3H/HeJ,
129S1/Sv and BALB/cJ) and non-permissive (C57BL/6J and DBA/2J) mouse background
strains that either allow survival or result in neonatal mortality, respectively, when bearing
deletions within the PWS critical region on chromosome 7C (Chamberlain et al., 2004;
Gerard et al., 1999). To compare background-dependent phenotypic differences between
5HT2C-VGV mutant mice and other PWS models, 129S6-derived heterozygous 5HT2C-VGV
dams were mated with wild-type C57BL/6J males. Offspring were genotyped at weaning or
at the time of death to reveal a completely penetrant neonatal lethality for hemizygous
mutant males, with 75% dying between P8-P12 and none surviving beyond P15 (Fig. 7;
p≤0.0001). These results are similar to the early neonatal lethality observed for other mouse
models of PWS on the C57BL/6 background (Chamberlain et al., 2004; Gerard et al., 1999)
and further indicate that while a single mutant 5HT2C allele can cause alterations in growth
and receptor expression in both hemizygous males and heterozygous females (Fig. 4) (U. B.
Olaghere da Silva, 2009), the presence of a single wild-type allele is sufficient for survival
on a non-permissive background strain (Fig. 7).
Discussion
The editing of 5HT2C transcripts modulates multiple aspects of 5HT2C receptor signaling
and expression in heterologous systems (Berg et al., 2001; Burns et al., 1997; Fitzgerald et
al., 1999; Flomen et al., 2004; Marion et al., 2004; Niswender et al., 1999; Price et al., 2001;
Wang et al., 2000), yet the physiologic importance for the existence of multiple 5HT2C
isoforms has not been fully explored. Recent studies by Kawahara et al. have characterized
mutant mice comparable to those described in the present study in which 5HT2C expression
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was limited to the fully-edited (VGV) isoform. These animals exhibited several similar
phenotypic alterations, including reduced pre-weaning growth, post-weaning hyperphagia
and an increased metabolic rate resulting from excessive activation of the sympathetic
nervous system (Kawahara et al., 2008), yet several differences between these mutant lines
also were readily apparent. Mice solely expressing the VGV isoform were previously
reported to exhibit reduced locomotor activity in an open field chamber (Kawahara et al.,
2008). While similar results were observed with 5HT2C-VGV mice using such a behavioral
paradigm (data not shown), these animals exhibited normal activity in their home cage
whether quantified by infrared motion detection (Fig. 5B) or wheel running (data not
shown). This suggests that mice solely expressing the fully-edited 5HT2C isoform do not
exhibit baseline hypoactivity, but rather decreased activity in a novel environment. Unlike
the dramatic increase in 5HT2C receptor expression observed in 5HT2C-VGV animals using
both radioligand binding (Fig. 3A) and Western blotting (Fig. 3B) analyses, the mutant
animals described by Kawahara et al. did not exhibit any increase in 5HT2C receptor protein
when analyzed by Western blotting (Kawahara et al., 2008). This result is particularly
surprising given that 5HT2C-selective autoradiographic analyses by Kawahara et al. revealed
an increase in receptor expression that was inconsistent with the Western blotting studies for
these animals (Kawahara et al., 2008).
The 40-to-70-fold increase in total 5HT2C receptor protein observed in 5HT2C-VGV mutant
animals (Fig. 3) was unexpected, given the minor nature of the mutations introduced into
exon 5 of the endogenous htr2C locus (Figs. 1A and B) and the fact that there were no
observed alterations in the steady-state levels of 5HT2C transcripts (Fig. 6B). Although a
27% increase in the production of RNA 2 was observed in mutant mice (Figs. 2C and D),
the dramatic increase in functional 5HT2C protein levels cannot be explained readily by this
small alteration in 5HT2C splice-site selection. Increased receptor protein could represent an
adaptive mechanism to compensate for the diminished coupling efficacy and constitutive
activity of the 5HT2C-VGV isoform that was observed initially in transfected cell lines (Burns
et al., 1997;Fitzgerald et al., 1999;Niswender et al., 1999;Wang et al., 2000). The absence of
a change in total 5HT2C transcripts for mutant animals indicates the existence of previously
unrecognized post-transcriptional mechanism(s) to regulate 5HT2C receptor density that
could be mediated by potential differences in translation efficiency and/or stability for
distinct edited receptor isoforms. Recent studies by Marion et al. have provided a potential
mechanism for isoform-specific differences in protein stability based upon a constitutive
activity-dependent alteration in the subcellular compartmentalization of the receptor,
resulting from an inability of highly edited 5HT2C receptor isoforms to effectively interact
with β-arrestin2 (Marion et al., 2004).
While the hyperphagia observed in 5HT2C-VGV mutant mice is similar to that exhibited by
5HT2C receptor-null animals, null mutants develop adult-onset obesity with no change in
metabolic rate (Nonogaki et al., 2003; Nonogaki et al., 1998); however, 5HT2C-VGV mutant
mice display an increase in their resting energy expenditure in the absence of hyperactivity,
which likely compensates for the hyperphagia observed in these mutants to prevent the onset
of obesity. The orexigenic changes in hypothalamic POMC and NPY mRNA expression in
5HT2C-VGV mutant animals are consistent with the observed increase in relative food
consumption (Fig. 5A). These data support previous evidence for a functional role for
5HT2C receptors in the modulation of food intake via a POMC-mediated mechanism,
including the expression of 5HT2C transcripts in ~80% of POMC neurons within the arcuate
nucleus of the hypothalamus (Heisler et al., 2002) and recent studies demonstrating that the
selective ablation of 5HT2C in these neurons is sufficient to eliminate the effects of
serotonergic compounds on food intake and result in hyperphagia-mediated obesity (Xu et
al., 2008).
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Although multiple mouse models lacking expression of one or more PWS candidate genes
have implicated several loci with elements of the PWS phenotype, these models vary widely
in their capacity to recapitulate the human disorder (Table 2). Mouse models lacking
expression of individual genes located within the imprinted region on chromosome 7C
display either no obvious PWS characteristics (Jong et al., 1999;Tsai et al., 1999a;Tsai et al.,
1999b;Yang et al., 1998), neonatal lethality from respiratory distress (Gerard et al., 1999), or
body mass changes that never differ from wild-type animals by more than 10% (Bischof et
al., 2007). However, several functional deletions encompassing larger portions of the
imprinted region result in neonatal lethality preceded by a failure to thrive (Cattanach et al.,
1992;Chamberlain et al., 2004;Gerard et al., 1999;Tsai et al., 1999b;Yang et al., 1998). It is
important to note that none of the mouse models of PWS reported to date demonstrate either
the infertility or the morbid obesity characteristic of the human syndrome, suggesting that
mice may not be capable of manifesting the full spectrum of phenotypic changes associated
with this genetic disorder. Reasons for the limited PWS phenotype(s) observed in mice may
include species-specific differences in gene structure, function, cell-expression patterns,
neuroendocrine and metabolic pathways and/or modifier genes (Goldstone, 2004).
Mutant mice solely expressing the fully-edited isoform of the 5HT2C receptor display
several phenotypic characteristics of PWS, including a failure to thrive, decreased somatic
growth and neonatal muscular hypotonia, followed by post-weaning hyperphagia, in
addition to other similarities with mouse models of PWS where deletions within the
imprinting center on chromosome 7C result in strain-specific neonatal lethality. These
observations are consistent with recent analyses indicating that 5HT2C RNA editing is
increased in autopsy samples from PWS patients (Kishore and Stamm, 2006) and a mouse
model (PWS-ICdel) that also demonstrates alterations in 5HT2C-related behaviors (Doe et
al., 2009). Previous studies have shown that the maternally imprinted snoRNA, HBII-52,
can alter both the splicing and editing of 5HT2C transcripts (Kishore and Stamm, 2006),
providing a provoking and straightforward mechanism by which to link the 5HT2C-VGV
mutation with the 15q11-13 locus and multiple aspects of this disorder. However, several
clinical cases have been identified recently that either suggest deletion of this snoRNA is not
sufficient to cause a PWS-like phenotype (Runte et al., 2005) or that a specific paternal
deletion of the HBII-85 snoRNA cluster can result in PWS (de Smith et al., 2009; Gallagher
et al., 2002; Sahoo et al., 2008). Due to the nature of these human clinical studies however,
it was impossible to assess potential changes in the brain-specific expression of other
snoRNAs in these patients, negating the ability of such studies to conclusively eliminate a
role for HBII-52. The generation of mutant mice bearing similar deletions have produced
animals with multiple PWS-like phenotypes (Table 2) and have shown the expression of
MBII-52 snoRNAs in the brains of these mutant animals, suggesting that the absence of
MBII-52 alone is not sufficient to cause this syndrome (Ding et al., 2008; Ding et al., 2005;
Skryabin et al., 2007). While most recent clinical and mouse studies have focused upon the
HBII-85 snoRNA cluster as playing a causal role in PWS (de Smith et al., 2009; Ding et al.,
2008; Gallagher et al., 2002; Runte et al., 2005; Skryabin et al., 2007), the targets of these
imprinted snoRNAs remain largely unknown, raising the possibility that alternative
mechanisms exist by which genes located within the 15q11-13 locus can alter 5HT2C
receptor function independent of HBII-52 expression.
The present studies have demonstrated that alterations in the normal pattern(s) of editing can
result in significant changes in growth, metabolism and feeding behavior and also have
identified an unknown post-transcriptional mechanism to modulate 5HT2C receptor density.
Given the ability of the 5HT2C-VGV mutation to phenocopy the failure-to-thrive, reduced
early-postnatal growth, hypotonia, adult hyperphagia, and strain-specific lethality observed
in previously-described mouse models of PWS (Table 2), these results strongly suggest a
link between altered 5HT2C receptor function and the development of major criteria
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necessary for the diagnosis of this disorder (Gunay-Aygun et al., 2001). Though this model
may implicate increased 5HT2C RNA editing in the molecular etiology of PWS, it does not
suggest that the full spectrum of altered phenotypes observed in PWS patients result solely
from altered 5HT2C receptor function. When combined with previously identified alterations
in 5HT2C-mediated behaviors in PWS-ICdel mice (Doe et al., 2009), observed increases in
the editing of 5HT2C transcripts in both mouse model of PWS and human patients (Doe et
al., 2009;Kishore and Stamm, 2006), and the known involvement of the 5HT2C receptor in
controlling energy homeostasis and satiety (Hewitt et al., 2002;Somerville et al., 2007;Xu et
al., 2008), the presence of PWS-like phenotypes in mice with altered 5HT2C editing
identifies the htr2C gene as the first locus outside the 15q11-13 imprinted region in which
mutations can recapitulate multiple aspects of this human genetic disorder.
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Targeting strategy and genotype analysis for 5HT2C-VGV mice. (A) The predicted secondary
structure for 5HT2C pre-mRNA near the distal end of exon 5 is presented. The positions of
the five editing sites (A-E) are shown with site-specific adenosine to guanosine mutations
indicated in red. (B) Schematic diagram and abbreviated restriction map of the mouse
5HT2C gene before and after targeted gene modification; the location of exon 5, the loxP
sites (▶) flanking the PGK/neomycin resistance cassette, the negative selectable marker
(PGK/TK) outside the region of homology, the approximate position of the introduced
mutations (*) and sequences outside the region of homology (dotted line) are indicated; Av,
Avr II; N, Not I; A, Acc I; K, Kpn I; S, Sfi I. (C) Genotype analysis of offspring from a
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hemizygous 5HT2C-VGV male (VGV/Y) x heterozygous mutant female (VGV/+) mating;
migration positions of PCR amplicons corresponding to the wild-type (371 bp) or mutant
(468 bp) 5HT2C alleles and animal genotypes are indicated. (D) Sequence electropherogram
traces of 5HT2C receptor-derived RT-PCR products generated from wild-type and
5HT2C-VGV hemizygous male mice. The positions of the five editing sites and the
corresponding nucleotide sequences are indicated; R, purine.
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Analysis of 5HT2C mRNA expression in wild-type and 5HT2C-VGV mice. (A) A schematic
diagram of a portion of the 5HT2C gene is shown in which 5′-splice site selection can
generate three alternatively spliced 5HT2C transcripts (RNA 1, RNA 2 and RNA 3). The
relative positions of contiguous antisense riboprobes used for ribonuclease protection
analysis (bold lines) to quantify either total 5HT2C mRNA (1+2+3) or the three individual
5HT2C splice variants is presented with the size of the expected protected fragment
(nucleotides, nt) for each mRNA isoform; the location of the 5 editing sites is indicated in
red. (B) Ribonuclease protection analysis of total 5HT2C mRNA expression (1+2+3) in
whole brain and dissected brain regions for 5HT2C-VGV (■) male mice is presented as a
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percentage of mean wild-type (□) expression; mean ± SEM, n ≥ 4 animals/genotype for
whole brain samples and n ≥ 6 animals/genotype for dissected brain regions. Inset,
Representative ribonuclease protection analysis of total 5HT2C RNA expression in whole
brain and dissected brain region samples from individual mice; WB, whole brain; Hy,
hypothalamus; OB, olfactory bulb; Cx, frontal cortex; Hi, hippocampus. (C) Quantitative
analysis of the relative expression levels for 5HT2C alternative splicing variants (RNA 1 and
RNA 2) in whole brain samples from wild-type (□) and 5HT2C-VGV (■) male mice (mean ±
SEM; n=7; **p ≤ 0.01). Inset, Representative ribonuclease protection analysis of
alternatively spliced 5HT2C RNAs in whole brain samples from individual mice. (D) Semi-
quantitative analysis of 5HT2C mRNA splicing patterns in wild-type and 5HT2C-VGV male
mice. Quantification of each 5HT2C splice variant is presented as a percentage of total
5HT2C mRNA expression (n=7; mean ± SEM; ***p ≤ 0.001); inset, Representative RT-
PCR amplification using common primers in exons 5 and 6 to detect three 5HT2C mRNA
isoforms; the expected migration positions of amplicons corresponding to each 5HT2C splice
variant are indicated.
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Analysis of 5HT2C protein expression in wild-type and 5HT2C-VGV mice. (A) Saturation
binding isotherms demonstrating 5HT2C receptor-specific binding for total membranes
prepared from dissected cortex, striatum and hippocampus in wild-type (□) and 5HT2C-VGV
(●) male mice (wild-type, n=4 groups of five pooled mice per brain region; 5HT2C-VGV, n=7
brain regions from individual animals; mean ± SEM). (B) Western blotti ng analysis of
5HT2C receptor and β-actin expression in whole brain samples isolated from individual
wild-type and 5HT2C-VGV male mice at postnatal day 2 (P2) or in adulthood (14-16 weeks);
n ≥ 8 for mice of each genotype, two representative samples are shown for each age and
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genotype. Representative Western blotting controls from NIH-3T3 cells stably expressing
either 5HT2A or 5HT2C receptors are presented.
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Body weight analysis of wild-type and 5HT2C-VGV mice. (A) Pre- and (B) post-weaning
growth curves are shown for wild-type and 5HT2C-VGV mutant mice (mean ± SEM; n=6 for
each genotype and gender; p ≤ 0.0001 using two-way ANOVA). Inset, A representative
photograph of wild-type and mutant (VGV/Y) littermates at postnatal day 21 is presented.
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Feeding behavior and metabolic analysis of wild-type and 5HT2C-VGV mice. (A) Food
intake for 15-week old male wild-type (□) and 5HT2C-VGV (■) mice per 24-hours (hr), 12-hr
light, or 12-hr dark period, corrected for total body mass (mean ± SEM, n=6, *p ≤ 0.05). (B)
Average daily activity detected by infrared sensors for wild-type (□) and 5HT2C-VGV adult
(■) mice maintained in a 12hr-12hr light/dark environment (mean ± SEM; n=6). (C) Indirect
calorimetric analysis of energy expenditure for wild-type (□) and 5HT2C-VGV (■) mice per
24-hr, while resting, or while active, corrected for total body mass (mean ± SEM, n=6, *p ≤
0.05). (D) Quantitative analysis of hypothalamic POMC and NPY mRNA expression at 0.5
weeks (n=4), 3 weeks (n=8), 14 weeks (n=12) and 36 weeks (n=11) in wild-type and
5HT2C-VGV male mice (mean ± SEM, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
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Analysis of muscle strength in wild-type and 5HT2C-VGV mice. (A) Motor coordination and
endurance of post-weaning (P22-P28, n=10) and adult (25 weeks, n=12) wild-type (□) and
5HT2C-VGV mutant (■) male mice (mean ± SEM; *p ≤0.05, **p ≤ 0.01, ***p ≤ 0.001). (B)
Average grip strength of recently weaned (P21-P28; n=5) or adult (n=7) wild-type (□) and
mutant (■) mice (mean ± SEM; ***p ≤ 0.001).
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Strain-specific lethality in 5HT2C-VGV mice. Cumulative survival rate for offspring resulting
from the mating of heterozygous mutant 129S6 females (VGV/+) to wild-type C57BL/6
males (n=28, +/Y; n=32, VGV/Y; n=33, +/+; n=17, VGV/+).
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